Protein-bound Uremic Toxins: New Culprits of Cardiovascular Events in Chronic Kidney Disease Patients

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2014 Feb 25

PMID 24561478

Citations 62

Authors

Shunsuke Ito

Masayuki Yoshida

Affiliations

Soon will be listed here.

Abstract

Chronic kidney disease (CKD) has been considered a major risk factor for cardiovascular diseases. Although great advances have recently been made in the pathophysiology and treatment of cardiovascular diseases, CKD remains a major global health problem. Moreover, the occurrence rates of cardiovascular events among CKD patients increase even in cases in which patients undergo hemodialysis, and the mechanisms underlying the so-called "cardiorenal syndrome" are not clearly understood. Recently, small-molecule uremic toxins have been associated with cardiovascular mortality in CKD and/or dialysis patients. These toxins range from small uncharged solutes to large protein-bound structures. In this review, we focused on protein-bound uremic toxins, such as indoxyl sulfate and p-cresyl sulfate, which are poorly removed by current dialysis techniques. Several studies have demonstrated that protein-bound uremic toxins, especially indoxyl sulfate, induce vascular inflammation, endothelial dysfunction, and vascular calcification, which may explain the relatively poor prognosis of CKD and dialysis patients. The aim of this review is to provide novel insights into the effects of indoxyl sulfate and p-cresyl sulfate on the pathogenesis of atherosclerosis.

Citing Articles

Structure-based discovery of a new type of scaffold compound as binding competitors for protein-bound Uremic Toxins.

Wang P, Liu S, Zhao S, Wang Y Sci Rep. 2024; 14(1):28152.

PMID: 39548203 PMC: 11568142. DOI: 10.1038/s41598-024-78766-9.

Effects of Propolis Supplementation on Gut Microbiota and Uremic Toxin Profiles of Patients Undergoing Hemodialysis.

Fonseca L, Ribeiro M, Schultz J, Borges N, Cardozo L, Leal V Toxins (Basel). 2024; 16(10).

PMID: 39453192 PMC: 11511383. DOI: 10.3390/toxins16100416.

Effects of resistant starch supplementation on renal function and inflammatory markers in patients with chronic kidney disease: a meta-analysis of randomized controlled trials.

Zhang Y, Hu X, Yang S, Hu Y, Duan K Ren Fail. 2024; 46(2):2416609.

PMID: 39444299 PMC: 11504232. DOI: 10.1080/0886022X.2024.2416609.

Metabolite profiling of human-originated Lachnospiraceae at the strain level.

Abdugheni R, Wang W, Wang Y, Du M, Liu F, Zhou N Imeta. 2024; 1(4):e58.

PMID: 38867908 PMC: 10989990. DOI: 10.1002/imt2.58.

Increased levels of a mycophenolic acid metabolite in patients with kidney failure negatively affect cardiomyocyte health.

Harlacher E, Schulte C, Vondenhoff S, Schmitt-Kopplin P, Diederich P, Hemmers C Front Cardiovasc Med. 2024; 11:1346475.

PMID: 38510194 PMC: 10951386. DOI: 10.3389/fcvm.2024.1346475.

References

Shimizu H, Yisireyili M, Higashiyama Y, Nishijima F, Niwa T . Indoxyl sulfate upregulates renal expression of ICAM-1 via production of ROS and activation of NF-κB and p53 in proximal tubular cells. Life Sci. 2012; 92(2):143-8. DOI: 10.1016/j.lfs.2012.11.012. View

Luo F, Patel K, Marquez I, Plummer N, Hostetter T, Meyer T . Effect of increasing dialyzer mass transfer area coefficient and dialysate flow on clearance of protein-bound solutes: a pilot crossover trial. Am J Kidney Dis. 2009; 53(6):1042-9. PMC: 10355144. DOI: 10.1053/j.ajkd.2009.01.265. View

Watanabe H, Miyamoto Y, Honda D, Tanaka H, Wu Q, Endo M . p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int. 2013; 83(4):582-92. DOI: 10.1038/ki.2012.448. View

Meijers B, van Kerckhoven S, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts M . The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis. 2009; 54(5):891-901. DOI: 10.1053/j.ajkd.2009.04.022. View

Schroeder J, Dinatale B, Murray I, Flaveny C, Liu Q, Laurenzana E . The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry. 2009; 49(2):393-400. PMC: 2805781. DOI: 10.1021/bi901786x. View

Meyer T, Peattie J, Miller J, Dinh D, Recht N, Walther J . Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysate. J Am Soc Nephrol. 2007; 18(3):868-74. DOI: 10.1681/ASN.2006080863. View

Muteliefu G, Enomoto A, Jiang P, Takahashi M, Niwa T . Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrol Dial Transplant. 2009; 24(7):2051-8. DOI: 10.1093/ndt/gfn757. View

Lekawanvijit S, Kompa A, Wang B, Kelly D, Krum H . Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circ Res. 2012; 111(11):1470-83. DOI: 10.1161/CIRCRESAHA.112.278457. View

Steffel J, Luscher T, Tanner F . Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006; 113(5):722-31. DOI: 10.1161/CIRCULATIONAHA.105.567297. View

10.

Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P . Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 2002; 17(9):1684-8. DOI: 10.1093/ndt/17.9.1684. View

11.

Maeda K, Hamada C, Hayashi T, Shou I, Wakabayashi M, Fukui M . Long-term effects of the oral adsorbent, AST-120, in patients with chronic renal failure. J Int Med Res. 2009; 37(1):205-13. DOI: 10.1177/147323000903700125. View

12.

Ronco C, Haapio M, House A, Anavekar N, Bellomo R . Cardiorenal syndrome. J Am Coll Cardiol. 2008; 52(19):1527-39. DOI: 10.1016/j.jacc.2008.07.051. View

13.

OHare A, Johansen K . Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol. 2001; 12(12):2838-2847. DOI: 10.1681/ASN.V12122838. View

14.

Ueda H, Shibahara N, Takagi S, Inoue T, Katsuoka Y . AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial. 2007; 11(3):189-95. DOI: 10.1111/j.1744-9987.2007.00430.x. View

15.

Adesso S, Popolo A, Bianco G, Sorrentino R, Pinto A, Autore G . The uremic toxin indoxyl sulphate enhances macrophage response to LPS. PLoS One. 2013; 8(9):e76778. PMC: 3786936. DOI: 10.1371/journal.pone.0076778. View

16.

Fujii H, Nishijima F, Goto S, Sugano M, Yamato H, Kitazawa R . Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant. 2009; 24(7):2089-95. DOI: 10.1093/ndt/gfp007. View

17.

Foley R, Parfrey P, Sarnak M . Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 2001; 9(12 Suppl):S16-23. View

18.

Ranganathan N, Patel B, Ranganathan P, Marczely J, Dheer R, Pechenyak B . In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease. ASAIO J. 2006; 52(1):70-9. DOI: 10.1097/01.mat.0000191345.45735.00. View

19.

Nakamura T, Kawagoe Y, Matsuda T, Ueda Y, Shimada N, Ebihara I . Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res. 2004; 27(2):121-6. DOI: 10.1159/000077536. View

20.

Ito S, Osaka M, Higuchi Y, Nishijima F, Ishii H, Yoshida M . Indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of E-selectin. J Biol Chem. 2010; 285(50):38869-75. PMC: 2998130. DOI: 10.1074/jbc.M110.166686. View